Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 10/20 | 0.36 |
| ▸ | DRD2 | P14416 | 4/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.32 |
| ▸ | DRD4 | P21917 | 2/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4900315 | 0.90 | OPRL1 (0.40) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL4895198 | 0.88 | OPRL1 (0.38) | OPRL1DRD2DRD3DRD4 | |
| SCHEMBL4896296 | 0.79 | OPRL1 (0.39) | OPRL1OPRM1 | |
| SCHEMBL4695388 | 0.78 | OPRL1 (0.59) | OPRL1 | |
| SCHEMBL4980226 | 0.78 | OPRL1 (0.45) | OPRL1 | |
| SCHEMBL4980222 | 0.78 | OPRL1 (0.45) | OPRL1 | |
| SCHEMBL4698594 | 0.77 | OPRL1 (0.47) | OPRL1OPRM1 | |
| SCHEMBL4896202 | 0.77 | OPRL1 (0.34) | OPRL1 | |
| SCHEMBL4900212 | 0.76 | OPRL1 (0.36) | OPRL1 | |
| Trifluoroacetic Acid SCHEMBL4900055 | 0.75 | OPRL1 (0.56) | OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207665-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidinopropanoic Acid Compounds as Orl-1-Receptor Antagonists | PFIZER INC. | 2008-08-28 | — | — | US | claimed |
| US-20080207665-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidinopropanoic Acid Compounds as Orl-1-Receptor Antagonists | PFIZER INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207665-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidinopropanoic Acid Compounds as Orl-1-Receptor Antagonists | PFIZER INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207665-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidinopropanoic Acid Compounds as Orl-1-Receptor Antagonists | PFIZER INC. | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207665-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidinopropanoic Acid Compounds as Orl-1-Receptor Antagonists | OPRL1, OGFRL1, OPRD1 | OPRL1 1/4885DRD2 1226/4885DRD3 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.